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ntagonists of 
 
 
 
v
 
 
 
3 and 
 
 
 
v
 
 
 
5 disrupt angiogenesis in
response to bFGF and VEGF, respectively. Here, we
show that these 
 
 
 
v integrins differentially contribute
to sustained Ras-extracellular signal–related kinase (Ras-ERK)
signaling in blood vessels, a requirement for endothelial cell
 
survival and angiogenesis. Inhibition of FAK or 
 
 
 
v
 
 
 
5 disrupted
VEGF-mediated Ras and c-Raf activity on the chick chorio-
allantoic membrane, whereas blockade of FAK or integrin
 
 
 
v
 
 
 
3 had no effect on bFGF-mediated Ras activity, but did
suppress c-Raf activation. Furthermore, retroviral delivery of
A
 
active Ras or c-Raf promoted ERK activity and angiogenesis,
which anti-
 
 
 
v
 
 
 
5 blocked upstream of Ras, whereas anti-
 
 
 
v
 
 
 
3 blocked downstream of Ras, but upstream of c-Raf. The
activation of c-Raf by bFGF/
 
 
 
v
 
 
 
3 not only depended on
FAK, but also required p21-activated kinase-dependent
phosphorylation of serine 338 on c-Raf, whereas VEGF-
mediated c-Raf phosphorylation/activation depended on Src,
but not Pak. Thus, integrins 
 
 
 
v
 
 
 
3 and 
 
 
 
v
 
 
 
5 differentially reg-
ulate the Ras-ERK pathway, accounting for distinct vascular
responses during two pathways of angiogenesis.
 
Introduction
 
Angiogenesis is regulated by signals derived from receptors
for both growth factors and ECM molecules (Eliceiri and
Cheresh, 2000). For example, inhibition of integrin 
 
 
 
v
 
 
 
3
during bFGF stimulation suppresses the sustained phase of
extracellular signal–related kinase (ERK) signaling (Eliceiri
et al., 1998) leading to endothelial apoptosis and inhibi-
tion of angiogenesis (Brooks et al., 1994a,b; Eliceiri et al.,
1998). Although anti-
 
 
 
v
 
 
 
3 blocks bFGF-mediated angio-
genesis, VEGF-induced angiogenesis is disrupted by anti-
 
 
 
v
 
 
 
5 (Friedlander et al., 1995), providing evidence that dis-
tinct signaling pathways regulate angiogenesis.
It is well recognized that cell proliferation requires both
growth factor stimulation and integrin-mediated adhesion to
the ECM (Aplin et al., 1999). A key mechanism by which
adhesion events influence cellular behavior is based on integrin-
mediated activation of the Ras-ERK cascade (Renshaw et al.,
1997), which regulates gene expression, cell proliferation,
survival, differentiation, and migration (Klemke et al., 1997;
Hood et al., 2002). A number of reports have characterized
the intracellular pathways leading to ERK activation in vitro
(Kolch, 2000). Previous reports reveal that growth factor
receptors or integrins recruit adaptor proteins and nucleotide
exchange factors that convert Ras to its GTP-bound form
leading to recruitment of c-Raf to the cytoplasmic membrane
where it can be activated (Feig and Cooper, 1988). Although
the mechanisms of c-Raf regulation are incompletely under-
stood, they are thought to involve membrane recruitment
and subsequent phosphorylation by protein kinases such as
p21-activated kinase (PAK) and Src, which are activated in
convergent cascades by growth factor receptors together with
integrins (Fabian et al., 1993; King et al., 1998; del Pozo et
al., 2000; Schlessinger, 2000). Recent reports indicate that
the differential phosphorylation of c-Raf by these kinases not
only regulates its activation in an on/off binary way, but also
controls its subcellular localization and subsequent distinct
cellular responses. Specifically, bFGF-induced phosphoryla-
tion of c-Raf on serine 338 by PAK leads to c-Raf transloca-
tion to the mitochondria and endothelial cell (EC) survival
in the face of apoptotic stress, whereas VEGF-induced
phosphorylation of c-Raf on tyrosines 340/341 by Src leads
to EC survival in response to receptor-mediated apoptosis
(Alavi et al., 2003).
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Although integrins and growth factor receptors promote
coordinated signaling activities, there appear to be multiple
mechanisms that govern how signals derived from these re-
ceptors converge. In vitro analyses have implicated Ras
(Schlaepfer et al., 1994), c-Raf (Lin et al., 1997), or MEK
(Renshaw et al., 1997) as a regulatory destination for inte-
grin signals in the ERK cascade. Based on previous reports
indicating that angiogenesis requires both an early, 
 
 
 
v inte-
grin–independent, and a sustained 
 
 
 
v-dependent activation
of ERK (Eliceiri et al., 1998), we sought to establish the
mechanisms by which 
 
 
 
v integrins influence the ERK path-
way during bFGF- versus VEGF-dependent neovasculariza-
tion within intact blood vessels. In this report, we present
the unexpected finding that 
 
 
 
v
 
 
 
3 and 
 
 
 
v
 
 
 
5, together with
 
FAK, play very distinct roles in the activation of the Ras-
ERK cascade leading to EC survival during angiogenesis in
response to bFGF and VEGF, respectively.
 
Results
 
 
 
v integrins contribute to sustained Ras, Raf-1, 
and ERK activation during angiogenesis in vivo
 
Antagonists of integrins 
 
 
 
v
 
 
 
3 and 
 
 
 
v
 
 
 
5 disrupt angiogene-
sis induced by bFGF and VEGF, respectively, in chick em-
bryos, mice, and rabbits (Friedlander et al., 1995, 1996).
These integrins potentiate growth factor–mediated, sus-
tained ERK signaling during angiogenesis, which is critical
for neovascularization in these tissues (Eliceiri et al., 1998).
Figure 1. FGF and VEGF require and stimulate Ras, Raf, and ERK activity during angiogenesis in cooperation with integrins  v 3 and  v 3. 
(A) 10-d-old chick CAMs were exposed to filter paper disks saturated with RCAS-Ras T17N (inactive Ras), RCAS-RafATP  (inactive c-Raf), or 
PD98059 (MEK inhibitor) followed by stimulation with either 2  g/ml bFGF or VEGF for 72 h. Blood vessels were enumerated by counting vessel 
branch points in a double-blinded manner. Each bar represents the mean   SEM of 24 replicates. *, P   0.05 relative to control; **, P   0.05 
relative to treatment. (B) 10-d-old chick CAMs were exposed to filter paper disks saturated with either bFGF or VEGF for 5 min, followed 
by excision and detergent extraction of the tissues. 1 h before excision, the embryos were i.v. injected with 30  g function-blocking antibodies 
selective for either integrin  v 3 (LM609) or  v 5 (P1F6). Relative Ras, c-Raf, and ERK was determined as described in Materials and methods. 
(C) Chick CAMs were treated as above with the exception that CAM tissue was excised 20 h after initial exposure to bFGF and VEGF.T
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Therefore, experiments were designed to establish how
 
 
 
v
 
 
 
3 and 
 
 
 
v
 
 
 
5 contribute to the Ras-ERK pathway during
angiogenesis in response to bFGF versus VEGF. For this
purpose, bFGF or VEGF was used to stimulate the growth
of new blood vessels on chick chorioallantoic membranes
(CAMs) of 10-d-old embryos. CAMs treated with growth
factor for either 5 min (early) or 20 h (late/sustained) were
exposed to function-blocking antibodies selective for either
 
 
 
v
 
 
 
3 or 
 
 
 
v
 
 
 
5. Alternatively, tissues were transduced with a
retroviral vector encoding mutationally inactive forms of Ras
or c-Raf, or treated with PD98059, a pharmacological in-
hibitor of MEK.
As expected, disruption of Ras, c-Raf, or MEK activity in
these tissues suppressed angiogenesis induced with either
growth factor (Fig. 1). In the absence of integrin antagonists,
the activity of Ras, c-Raf, and ERK was induced within 5
min and remained active for at least 20 h after either bFGF
or VEGF stimulation (Fig. 1, B and C). Intravenous admin-
istration of anti-
 
 
 
v
 
 
 
3, either 1 h before growth factor addi-
tion, or 1 h before harvest at the 20-h time point, showed no
diminution of bFGF-induced early or late Ras activity in
CAM tissues (Fig. 1, B and C). However, anti-
 
 
 
v
 
 
 
3 did
prevent the bFGF-induced sustained c-Raf and ERK activity
(Fig. 1, B and C). In contrast, i.v. injection of anti-
 
 
 
v
 
 
 
5
completely blocked VEGF-mediated late Ras and c-Raf, as
well as ERK activity (Fig. 1, B and C). Importantly, anti-
 
 
 
v
 
 
 
3 did not suppress VEGF-induced, nor did anti-
 
 
 
v
 
 
 
5
suppress bFGF-induced Ras, c-Raf, or ERK signaling (Fig.
1, B and C). These findings suggest that ligation of specific
 
 
 
v integrins differentially regulates bFGF- and VEGF-medi-
ated activation of the Ras-ERK signaling pathway in angio-
genic tissue in vivo. In this case, VEGF-mediated (but not
bFGF-mediated) activation of Ras depends on the coordi-
nated ligation of a specific 
 
 
 
v integrin. Our findings can
likely be attributed to a direct effect on blood vessels because
VEGF preferentially activates ECs, and 
 
 
 
v
 
 
 
3 is exclusively
expressed by ECs within these tissues.
 
FAK is required for Ras-ERK activity 
and angiogenesis in vivo
 
FAK is stimulated on integrin ligation (Schaller, 2001) and
plays a critical role in growth factor signaling (Sieg et al.,
2000). To further evaluate the role of integrin signaling in
angiogenesis, we asked whether FAK activity was required
Figure 2.  FAK is required for angio-
genesis and signaling during bFGF- and 
VEGF-induced angiogenesis. (A) 10-d-old 
chick CAMs were exposed to filter paper 
disks saturated with RCAS(A)-FRNK 
(inactive FAK) or i.v. injected with anti-
 v 3 or - v 5 followed by stimulation 
with either 2  g/ml bFGF or VEGF for
72 h. Blood vessels were enumerated by 
counting vessel branch points in a double-
blinded manner. Each bar represents the 
mean   SEM of 20 replicates. *, P   0.05 
relative to control; **, P   0.05 relative to 
treatment. (B) 10-d-old chick CAMs were 
exposed to filter paper disks saturated 
with RCAS-FRNK (inactive FAK) followed 
by stimulation with either 2  g/ml bFGF 
or VEGF for 20 h. Tissues were then 
excised and subjected to detergent ex-
traction. Relative Ras activity was deter-
mined using a pulldown assay with the 
Ras-binding domain of c-Raf followed 
by SDS-PAGE and immunoblotting for 
Ras as described in Materials and methods. 
(C) Chick CAMs were treated as above 
with the exception that c-Raf was 
immunoprecipitated from the tissue 
extracts and subjected to an in vitro 
kinase assay using kinase-dead MEK as 
a substrate as described in Materials and 
methods. The above blot was probed 
with an anti-c-Raf antibody as a loading 
control. (D) Chick CAMs were treated as 
above with the exception that total CAM 
lysates were electrophoresed and probed 
with antibodies directed against the 
active phosphorylated form of ERK or an 
anti-ERK antibody as a loading control.T
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for angiogenesis and if so, how it might contribute to bFGF-
or VEGF-mediated Ras-ERK activation. For this purpose,
CAMs stimulated with either bFGF or VEGF were trans-
duced with a retrovirus encoding FAK-related nonkinase
(FRNK), an autonomously expressed form of FAK contain-
ing the COOH-terminal region of FAK, but lacking its ki-
nase domain. Consistent with analyses using integrin antag-
onists (Brooks et al., 1994a; Friedlander et al., 1995) and
reports examining FAK’s role in growth factor–induced
ERK activity and migration (Renshaw et al., 1999; Sieg et
al., 2000), blockade of FAK activity in these tissues dis-
rupted angiogenesis induced with either growth factor (Fig.
2 A). Although FAK was required for c-Raf and ERK activ-
ity in response to either growth factor, only Ras activity
downstream of VEGF was FAK dependent (Fig. 2, B–D).
These results are consistent with those obtained when anti-
 
 
 
v
 
 
 
3 and anti-
 
 
 
v
 
 
 
5 were applied to these tissues. Specifi-
cally, VEGF-mediated Ras activity requires FAK and 
 
 
 
v
 
 
 
5,
whereas bFGF activation of Ras is both FAK- and 
 
 
 
v
 
 
 
3-
independent. However, both growth factors require their re-
spective 
 
 
 
v integrin and FAK for activation of c-Raf and
ERK leading to angiogenesis.
 
Integrin antagonists differentially suppress 
angiogenesis in response to active Ras or Raf
 
To further establish the role 
 
 
 
v integrins play in Ras-Erk
signaling and angiogenesis, unstimulated CAMs were trans-
duced with active forms of Ras (G12V-Ras) or c-Raf (Raf-
Figure 3. Ras and Raf are differentially regulated by integrins  v 3 and  v 5 during bFGF- and VEGF-induced angiogenesis. (A) 10-d-old 
chick CAMs were exposed to filter paper disks saturated with either bFGF, VEGF, RCAS-Ras G12V (active Ras), or RCAS-Raf-caax (active c-Raf). 
After 20 h, embryos were i.v. injected with function-blocking antibodies directed against integrins  v 3 or  v 5. After 72 h, blood vessels 
were enumerated by counting vessel branch points in a double-blinded manner. Each bar represents the mean   SEM of 24 replicates. 
*, P   0.05 relative to control; **, P   0.05 relative to treatment. (B) Chick CAMs were treated as above with the exception that antibodies 
directed against integrin  v 3 were injected after 19 h of growth-factor stimulation followed by excision and detergent extraction 1 h later. 
Lysates were then electrophoresed and probed with antibodies directed against the active, phosphorylated form of ERK or an anti-ERK antibody 
as a loading control. (C) Chick CAMs were treated as above with the exception that antibodies directed against integrin  v 5 were injected 
after 19 h of growth-factor stimulation followed by excision and detergent extraction 1 h later. Lysates were then electrophoresed and probed 
with antibodies directed against the active, phosphorylated form of ERK or an anti-ERK antibody as a loading control.T
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caax), which promoted a strong angiogenic response in
these tissues (Fig. 3 A). CAMs stimulated with active Ras
or c-Raf were then treated with either anti- v 3 or - v 5
and analyzed for Ras or c-Raf activity after 20 h, or mea-
sured for angiogenesis after 72 h. Expression of active Ras
or c-Raf induced an equivalent or greater angiogenic re-
sponse compared with that seen with bFGF or VEGF (Fig.
3 A). Although anti- v 3 blocked bFGF as well as Ras-
mediated angiogenesis, it had little effect on that induced
with c-Raf, suggesting that  v 3 potentiates signaling to
ERK downstream of Ras, but at or upstream of c-Raf. In
contrast, anti- v 5 blocked VEGF-induced angiogenesis,
yet had no effect on angiogenesis induced with activated
Ras or c-Raf, suggesting that the anti-angiogenic effects of
anti- v 5 was upstream of both Ras and c-Raf. These re-
sults are consistent with the finding that anti- v 5 blocks
VEGF-mediated Ras activity, whereas anti- v 3 disrupts
bFGF-mediated c-Raf activation, but fails to block Ras ac-
tivation.
To extend these experiments, ERK activity was assessed in
extracts of CAMs stimulated as described in the previous para-
graph. Consistent with the angiogenesis results (Fig. 3 A),
anti- v 3 blocked bFGF as well as Ras-mediated ERK activa-
tion in these tissues, but failed to influence that induced by
Raf-caax. However, anti- v 5 failed to block Ras- or c-Raf–
induced ERK activity, but it did disrupt VEGF-mediated
ERK activation (Fig. 3, B and C). Together, these results sup-
port the finding that integrins  v 3 and  v 5 influence the
Ras-ERK pathway at distinct points (Fig. 1 and Fig. 2).
Src requirement for Raf-ERK activation during
VEGF-induced (but not bFGF-induced) angiogenesis
Previous reports have documented that VEGF-mediated
(but not bFGF-mediated) angiogenesis depends on the ac-
tivity of Src family kinases (Eliceiri et al., 1999) and  v 5
(Friedlander et al., 1995). To evaluate whether  v 5 sig-
naling is linked to Src’s role in angiogenesis, CAMs stimu-
lated with bFGF or VEGF and treated with anti- v 3 or
- v 5, respectively, were lysed and analyzed for Src activ-
ity. Although both growth factors stimulated Src activity,
neither antibody was able to suppress this response (Fig. 4
A), which is consistent with previous findings that Src ac-
tivity is upstream of integrin signaling on the VEGF path-
way (Eliceiri et al., 2002). Notably, Src can also regulate
c-Raf activation by phosphorylating c-Raf on tyrosines
340/341 (Fabian et al., 1993), a site phosphorylated in re-
sponse to stimulation by VEGF, but not bFGF (Alavi et
al., 2003). To evaluate the role of  v 5 in VEGF-induced
c-Raf phosphorylation, CAMs stimulated with bFGF or
VEGF were treated with either anti- v 3 or - v 5, re-
spectively, and c-Raf was analyzed for phosphorylation of
tyrosines 340/341 (Fig. 4 B). In agreement with earlier re-
ports (Alavi et al., 2003), VEGF (but not bFGF) induced
phosphorylation of Raf on tyrosines 340/341. However,
this phosphorylation event was completely blocked by in-
hibition of integrin  v 5. To confirm the role of Src in
VEGF-induced c-Raf activation, CAMs stimulated with
bFGF or VEGF were transduced with RCAS-Src251 or
treated with the Src inhibitor PP1 and subsequently ana-
Figure 4. Src requirement for Raf-ERK 
activation during VEGF-induced 
(but not bFGF-induced) angiogenesis. 
(A) 10-d-old chick CAMs were exposed 
to filter paper disks saturated with either 
bFGF or VEGF for 20 h, followed by 
excision and detergent extraction of the 
tissues. 1 h before excision, the embryos 
were 1.v. injected with 30  g function-
blocking antibodies selective for either 
integrin  v 3 or  v 5 as indicated. 
Endogenous Src was immunoprecipitated 
and subjected to an in vitro kinase assay 
using a FAK-GST fusion protein as a 
substrate, electrophoresed, and anti-Src 
antibody was used as a loading control 
as described in Materials and methods. 
(B) 10-d-old chick CAMs were treated 
as described above with the exception 
that after excision, c-Raf was immuno-
precipitated from the tissue extracts 
and probed with an antibody directed 
against phosphorylated tyrosine 340 on 
c-Raf. The above blot was then stripped 
and probed with an anti-c-Raf antibody 
as a loading control. (C) Chick CAMs 
were stimulated as described above with 
the exception that filter paper disks 
on the CAM were saturated with either 
the Src inhibitor PP1 or RCAS-Src251 
(inactive Src), followed by blotting for 
phospho-Raf 340 or anti-c-Raf. (D) Chick CAMs were stimulated as described above with the exception that lysates were probed with 
antibodies directed against the active, phosphorylated form of ERK or an anti-ERK antibody as a loading control.T
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lyzed for phosphorylation of c-Raf at tyrosines 340/341
(Fig. 4 C). Consistent with a direct role for Src in VEGF-
mediated c-Raf activation, VEGF-induced (but not bFGF-
induced) phosphorylation of c-Raf on tyrosines 340/341
was blocked by treatment of tissues with Src251 or PP1.
Furthermore, VEGF (but not bFGF) induced ERK activity
that was completely abolished by Src251 or PP1 (Fig. 4
D). These findings reveal that VEGF/ v 5 selectively use
Src to phosphorylate c-Raf in vivo, leading to ERK activa-
tion and angiogenesis.
 v 3 contributes to bFGF-induced PAK-1 activation, 
which is required for bFGF-mediated (but not
VEGF-mediated) Raf-ERK activation and angiogenesis
The finding that  v 3 appears to regulate c-Raf, but not
Ras activity in response to bFGF prompted us to evaluate
how  v 3 contributes to c-Raf activation. Recently, we
found that bFGF-mediated angiogenesis is dependent on
PAK-1 signaling (Kiosses et al., 2002). Importantly, PAK-1
phosphorylates c-Raf on serine 338, leading to its activa-
tion (Zang et al., 2002). To evaluate whether  v 3 signal-
ing is linked to PAK-1’s role in angiogenesis, CAMs stimu-
lated with bFGF or VEGF and treated with anti- v 3 or
- v 5 were lysed and analyzed for PAK-1 activity. Al-
though both growth factors stimulated PAK activity, only
anti- v 3 was able to suppress this response (Fig. 5 A). Ac-
cordingly, direct evaluation of the tissue lysates revealed
that bFGF (but not VEGF) induced an  v 3-dependent
phosphorylation of c-Raf at its PAK phosphorylation site,
S338 (Fig. 5 B). These findings were confirmed by in situ
evaluation of CAM tissue sections, revealing that the phos-
pho-Raf 338 staining was primarily associated with bFGF-
stimulated blood vessels (Fig. 5 C).
Consistent with these results, transduction of CAMs with
an RCAS retrovirus encoding the PAK-1 auto-inhibitory
domain (PAK83–149; Zhao et al., 1998) selectively disrupted
bFGF-induced ERK activity (Fig. 6 A) in these tissues. This
finding was confirmed in situ, using an antibody specific for
phosphorylated (activated) ERK, which revealed that the
suppression of PAK-1 selectively blocked bFGF-mediated
ERK activation within angiogenic blood vessels (Fig. 6
B). These findings were extended by evaluating angiogene-
sis on CAMs stimulated with VEGF- and bFGF-mediated
or bFGF and transduced with RCAS-PAK83–149. Although
both growth factors stimulated angiogenesis, inhibition of
PAK-1 selectively suppressed bFGF-induced angiogenesis
(Fig. 6 C). These findings reveal that integrin  v 3 regu-
lates PAK-1 activity during bFGF-induced angiogenesis in
vivo, and that PAK-1 selectively mediates bFGF-induced
ERK activation and angiogenesis.
Figure 5. Integrins  v 3 and  v 5 differentially influence PAK activity during angiogenesis. (A) 10-d-old chick CAMs were exposed to filter 
paper disks saturated with RCAS-FRNK (inactive FAK), followed by stimulation with either 2  g/ml bFGF or VEGF for 20 h. 1 h before tissue 
excision, function-blocking antibodies directed against integrin  v 3 or  v 5 were i.v. injected. Endogenous PAK was immunoprecipitated 
from equivalent amounts of total protein and subjected to a kinase assay using myelin basic protein as a substrate, electrophoresed, and trans-
ferred to nitrocellulose as described in Materials and methods. The above blot was probed with an anti-PAK antibody as a loading control. 
(B) Chick CAMs were treated as above with the exception that total lysates were probed with an antibody directed specific to c-Raf phosphorylated 
at serine 338. The above blot was probed with an anti-c-Raf antibody as a loading control. (C) Chick CAMs were treated as above with the 
exception that after 20 h, the angiogenic tissue was resected and snap frozen. Tissue sections were probed with an antibody directed against 
c-Raf phosphorylated at serine 338. Bar, 50  m.T
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Discussion
Recent evidence suggests that activation of the Ras-ERK sig-
naling pathway is critical for vasculogenesis and angiogenesis
(Eliceiri et al., 1998; Giroux et al., 1999; Huser et al., 2001;
Hood et al., 2002). Although it is established that cell inter-
action with growth factors and ECM components ultimately
lead to Ras-ERK activation, little is known of how integrins
and growth factor receptors coordinate their intracellular
signaling pathways. The current analyses address how bFGF
and VEGF and  v integrin-derived signals are coordinated
within ECs undergoing angiogenesis in vivo.
In this report, evidence is provided that distinct integrin/
growth factor receptor pairs differentially activate the Ras-
ERK cascade during angiogenesis (Fig. 7). Consistent with
earlier reports, blocking  v integrin ligation selectively in-
hibited the late-acting sustained ERK activity (Fig. 1) that
is critical for angiogenesis (Eliceiri et al., 1998), and in-
hibition of integrin  v 3 or  v 5 selectively inhib-
ited bFGF- or VEGF-mediated angiogenesis, respectively
(Friedlander et al., 1995). Although  v integrins appear to
control sustained/late Ras-ERK signaling, the initial signal-
ing response to these angiogenic growth factors may be
supported by preexisting EC integrins such as  2 1 and
 1 1, which also contribute to angiogenesis (Senger et al.,
2002). In the current work, we found that coordinated sig-
nals from integrins  v 3 or  v 5 together with bFGF or
VEGF, respectively, induce angiogenesis in a manner that
is dependent on activation of FAK, Ras, c-Raf, and ERK.
However, there was surprising disparity in how these inte-
grin-growth factor pairs activated the Ras-ERK pathway,
and thereby likely influence EC survival (Alavi et al., 2003)
and angiogenesis (Fig. 7).
Integrin ligation leads to activation of FAK, which is
known to mediate downstream signaling (Schlaepfer et al.,
1999), facilitating serum-induced activation of ERK in NIH
3T3s (Renshaw et al., 1999) and growth factor–dependent
cell migration (Sieg et al., 2000). Notably, our results in-
dicate that although disrupting FAK mirrors some of the
effects of integrin antagonists, it had no impact on  v 3-
mediated PAK activation (Fig. 5), a requirement for bFGF-
mediated c-Raf activity. These findings indicate that during
angiogenesis, some critical integrin signaling is independent
of FAK activity. In this case, it is possible that the small
GTPase Rac, which has been reported to be both activated
by integrins and essential for PAK activation (del Pozo et al.,
2000), is responsible for the FAK-independent,  v 3-
induced activation of PAK after bFGF stimulation.
Although the importance of FAK in integrin signaling is
well established, its role in angiogenesis is not entirely clear.
Experiments presented here indicate that although FAK is
required for c-Raf and ERK activation during bFGF-medi-
ated angiogenesis, it is not required for bFGF-mediated Ras
activation (Fig. 2). These results are consistent with reports
indicating that integrins influence growth factor–induced
activation of the ERK cascade in a manner downstream of
Ras (Chen et al., 1996; Renshaw et al., 1997), and that FAK
can signal directly to c-Raf (Barberis et al., 2000). However,
this was not the case for VEGF activation of Ras because
 v 5 ligation (Fig. 1) and FAK activity (Fig. 2) were found
to play a critical role in Ras activation. Therefore, the role of
Figure 6. PAK activity is required for bFGF-mediated ERK activation and angiogenesis. (A) 10-d-old chick CAMs were exposed to filter 
paper disks saturated with RCAS-PAK83–149 (inactive PAK), followed by stimulation with either 2  g/ml bFGF or VEGF for 20 h. CAM tissue 
was excised, subjected to detergent extraction, electrophoresed, and probed with antibodies directed against the active phosphorylated form 
of ERK or an anti-ERK antibody as a loading control as described in Materials and methods. (B) Chick CAMs were treated as above with the 
exception that after 20 h, the angiogenic tissue was resected and snap frozen. Tissue sections were probed with an antibody directed against 
the active phosphorylated form of ERK. (C) 10-d-old chick CAMs were exposed to filter paper disks saturated with RCAS-PAK83–149 (inactive PAK), 
followed by stimulation with either bFGF or VEGF for 72 h. Blood vessels were enumerated by counting vessel branch points in a double-
blinded manner. Each bar represents the mean   SEM of 36 replicates. *, P   0.05 relative to control; **, P   0.05 relative to treatment.T
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 v 5 in VEGF-induced Ras-ERK activation appears to be
limited to signaling through FAK to Ras, which is in stark
contrast to the role FAK and  v 3 play in bFGF-induced
Raf-ERK activation (Fig. 7).
Previous reports have revealed that although Ras activa-
tion is necessary for c-Raf activity, it is not sufficient (Yip-
Schneider et al., 2000). For example, activation of c-Raf
requires uncoupling of the 14–3–3 adaptor protein, asso-
ciation with activated Ras at the plasma membrane, and
phosphorylation by various protein kinases. At the mem-
brane, c-Raf activity can be modulated by phosphorylation
of at least 11 tyrosine and serine/threonine residues. De-
pending on which sites are phosphorylated, c-Raf activity
can be either elevated or diminished (Chong et al., 2003).
Several kinases are capable of modulating c-Raf, yet the mo-
lecular mechanisms responsible for c-Raf activation within
intact tissues remain unclear. Our findings reveal that the
pathway leading to c-Raf activation varies within blood ves-
sels undergoing angiogenesis, depending on the growth fac-
tor used to stimulate the process. For example, bFGF elic-
ited an  v 3-dependent, PAK-mediated phosphorylation of
c-Raf at serine 338, a site at which VEGF-stimulated tissue
showed minimal phosphorylation (Fig. 5). Integrin-medi-
ated adhesion activates PAK through its effector Rac (del
Pozo et al., 2000), which enables PAK to activate c-Raf by
phosphorylation of serine 338 (King et al., 1998; del Pozo et
al., 2000; Drogen et al., 2000). Notably, phosphorylation of
these sites may be sufficient for c-Raf activity induced by in-
tegrin ligation (Chaudhary et al., 2000).
Although bFGF selectively used PAK to activate c-Raf,
VEGF makes use of the tyrosine kinase Src for this purpose.
Previous reports have shown that VEGF selectively uses Src
during VEGF-induced permeability increases and angiogen-
esis (Eliceiri et al., 1999), but the role of Src activity on
downstream signals such as Raf was unclear. Our work re-
veals that although  v 5 is not required for VEGF activa-
tion of Src, it is required for the subsequent Src-mediated
phosphorylation of Raf. Considering our current work and
previous findings (Eliceiri et al., 1999), Src appears to func-
tion both upstream and downstream of  v 5/FAK. Once
the VEGF receptor (Flk) becomes ligated, it recruits and ac-
tivates Src (He et al., 1999). This leads to tyrosine phos-
phorylation on several FAK sites, including tyrosine 861, al-
lowing FAK to couple to  v 5 (Eliceiri et al., 2002). This
potentiates   v 5/FAK signaling and activation of down-
stream signaling molecules including VEGF-induced FAK-
dependent Ras activation (Fig. 2). Subsequent to Ras
activation, Raf is recruited to the membrane where it is
phosphorylated by Src on tyrosines 340/341 (Fig. 4 and Fig.
7). This phosphorylation appears critical to the role that Src
plays in VEGF-mediated survival (Alavi et al., 2003). To-
gether, these findings support a multi-layered role for Src in
the VEGF/ v 5 signaling cascade. Consistent with this
conclusion, delivery of active Src to angiogenic tissues pro-
motes angiogenesis that was blocked by anti- v 5 (unpub-
lished data), and mice deficient in Src or  v 5 show no
VEGF-mediated vascular permeability increases, whereas
mice lacking  v 3 maintain their permeability response to
VEGF (Eliceiri et al., 2002).
Although coordinated signals from either VEGF/ v 5 or
bFGF/ v 3 result in angiogenesis, the differential activa-
tion of these signaling pathways may impact the distinct bio-
Figure 7. bFGF/ v 3 and VEGF/ v 5 signaling pathways. A summary of the signaling pathways outlined in this report as it relates to EC cell 
survival as recently described in Alavi et al. (2003). Evidence presented here reveals that bFGF/ v 3 and VEGF/ v 5 differentially activate 
Ras-Raf-ERK signaling. This, together with our recent work (Alavi et al., 2003), allows us to propose a model whereby each of these signaling 
pathways accounts for protection of EC from distinct mediators of apoptosis. The  v 3 pathway promotes an ERK-independent survival mechanism 
preventing stress-mediated death based on Raf coupling to the mitochondria, whereas the  v 5 pathway prevents receptor-mediated death 
in an ERK-dependent manner. In addition, ERK is likely playing a general role in both pathways of angiogenesis because it regulates gene 
transcription, cell cycle progression, and cell migration, which are critical to the growth and differentiation of new blood vessels.T
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logical responses of VEGF and bFGF. For example, even
though bFGF and VEGF both induce angiogenesis, only
VEGF is a potent vascular permeability factor (Gautschi et
al., 1986; Senger et al., 1986; Leung et al., 1989). However,
mice lacking either  v 3 or  v 5 show no angiogenic de-
fect (Reynolds et al., 2002), yet animals deficient in  v 5
fail to undergo VEGF-mediated permeability (Eliceiri et al.,
2002). Although it has been suggested that  v integrins neg-
atively regulate angiogenesis (Hynes, 2002), evidence is pre-
sented here that anti- v integrin function–blocking anti-
bodies, which antagonize these integrins, block activation of
Ras and/or Raf in response to angiogenic growth factors
such as bFGF and VEGF. Moreover, this differential activa-
tion of Raf has been directly linked to two pathways of EC
survival during angiogenesis (Alavi et al., 2003), as summa-
rized in Fig. 7. Therefore, it is very possible that mice defi-
cient in  v 3 and/or  v 5 may have up-regulated compen-
satory signaling mechanisms leading to EC cell survival. In
fact,   v 3-deficient mice up-regulate both VEGF and
VEGF receptor (Reynolds et al., 2002), demonstrating that
at least one survival factor and its receptor may be playing a
compensatory role in  v 3 KO mice. In addition, we re-
cently determined that mice deficient in p53 showed no
anti-angiogenic response when challenged with a cyclic pep-
tide antagonist of  v 3/ v 5, indicating that p53-deficient
mice may be genetically prone to using a survival pathway
that does not depend on  v integrin ligation (Stromblad et
al., 2002). In any event, removal of an integrin before devel-
opment is quite distinct from blocking one present on fully
formed blood vessels actively engaged in neovascularization.
We were interested to ask why there should be distinct
signaling pathways leading to the formation of new blood
vessels. To this end, we recently reported that bFGF and
VEGF selectively protect ECs from stress- and receptor-
mediated apoptosis, respectively, in a manner that is depen-
dent on the differential phosphorylation of c-Raf by PAK
and Src (Alavi et al., 2003). As depicted in Fig. 7, we have
integrated our current findings with our recent work (Alavi
et al., 2003), showing that FGF-mediated EC protection
from stress-mediated death is independent of ERK, yet also
dependent on phosphorylation of c-Raf at its PAK phos-
phorylation sites, S338, leading Raf translocation to the mi-
tochondria. In contrast, VEGF-mediated protection (Fig.
7) is mediated in part by its phosphorylation of c-Raf at its
Src phosphorylation sites, YY340/341 leading to an ERK-
dependent protection against receptor-mediated apoptosis
(Alavi et al., 2003). Intriguingly, although ERK likely plays
a role in bFGF-mediated cell proliferation, migration, and
differentiation (Eliceiri et al., 1998), it does not appear to
be essential for survival (Alavi et al., 2003). What remains
unclear is whether ERK itself is activated in the same man-
ner by both growth factor/integrin signaling pathways or
whether other ERK isoforms may be activated in response
to either pathway.
In the current report, we show that bFGF-induced PAK
activation and subsequent c-Raf activation are blocked by
inhibitors of  v 3 (Fig. 5). Intriguingly, stimulation by ei-
ther bFGF or VEGF activates PAK, but only bFGF/ v 3
signaling led to phosphorylation of Raf S338 (Fig. 5). Simi-
larly, both bFGF and VEGF stimulation activates Src, but
only VEGF signaling leads to an Src-dependent phosphory-
lation of c-Raf on Y340/341. This suggests that regulation
of signaling enzymes and subsequent biological events are
dependent on more than the sequential activation of en-
zymes in an on/off binary fashion, but is instead dependent
on the entire context of signals within the cell, some of
which are derived from specific ECM–integrin ligation
events and propagated by distinct  v integrins.
What, then, is the need for two growth factor/integrin
pairs to differentially influence EC survival during angiogen-
esis? This may be important for vascular pruning (Benjamin
et al., 1999) or regulation of blood vessel morphology and/
or function in specific microenvironments such as wounds
or inflammatory sites (Alon et al., 1995). In addition to
growth factor–mediated signals, ECM composition likely
influences the fate and integrity of newly sprouting blood
vessels based on the expression of specific integrins on the
EC surface (Alon et al., 1995; Stupack et al., 2001). In fact,
we recently demonstrated that certain unligated integrins
could induce “integrin-mediated death” (Stupack et al.,
2001), which may regulate angiogenesis by promoting EC
apoptosis, thereby only permitting the survival of appropri-
ately positioned ECs during vascular remodeling.
In summary, our results indicate that during angiogenesis,
VEGF and  v 5 or bFGF and  v 3 cooperate to differen-
tially regulate the activation of the Ras-ERK pathway.
VEGF uses  v 5 and FAK to activate Ras, along with Src to
activate c-Raf, whereas bFGF uses  v 3, FAK, and PAK
downstream of Ras to activate c-Raf. Either of these path-
ways leads to sustained Ras-ERK activity and subsequent an-
giogenesis, and the distinct signaling molecules activated
may play a role in the divergent vascular and survival re-
sponses elicited by bFGF and VEGF.
Materials and methods
Antibodies and reagents
Mouse mAbs raised against integrins  v 3 and  v 5 have been described
previously (Friedlander et al., 1995). A mouse mAb raised against p21-Ras
(Transduction Laboratories) was used for immunoblotting of loading con-
trols. A mouse mAb raised against c-Raf (Transduction Laboratories) was
used for immunoprecipitations for in vitro kinase assays and immunoblot-
ting. A phosphospecific antibody raised against ERK phosphorylated at
threonine 202/tyrosine204 (Cell Signaling Technologies) was used for im-
munoblots and immunofluorescence of active ERK. A rabbit pAb, C-14,
raised against rat ERK2 (Santa Cruz Biotechnology, Inc.) was used for im-
munoblotting of loading controls. A phosphospecific rat mAb raised
against c-Raf phosphorylated at serine 338 (Upstate Biotechnology) was
used for immunoblots and immunofluorescence. A phosphospecific rabbit
pAb raised against c-Raf phosphorylated at Serine 340 (Biosource Interna-
tional, Camarillo, CA) was used for immunoblots. A rabbit polyclonal anti-
body, N-20, raised against an NH2-terminal sequence of rat PAK (Santa
Cruz Biotechnology, Inc.) was used for immunoblotting and immunopre-
cipitations for in vitro kinase assays. The bFGF was a gift from Dr. J. Abra-
ham (Scios, Mountain View, CA), and PD98059 was the gift of Dr. A.
Saltiel (Parke-Davis, Ann Arbor, MI). All other reagents were from Sigma-
Aldrich unless otherwise stated.
Constructs and retroviruses
The replication-competent RCASBP(A) (Hughes et al., 1987) retrovirus was
used to express the described mutant cDNAs subcloned as NotI–ClaI.
These constructs were transfected into the chicken immortalized fibroblast
line DF-1. Viral supernatants were collected from DF-1 producer cell lines
in serum-free CLM media. Viral supernatants were concentrated by ultra-
centrifugation at 4 C for 2 h at 22,000 rpm, and the pellets were resus-
pended in 1/100 the original volume in serum-free media with a titer of atT
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least 108 infectious units (i.u.)/ml and stored at  80 C. RCAS-Raf-caax, a
dominant-active form of c-Raf generated by fusing the membrane targeting
region of Ras to c-Raf (Leevers et al., 1994; Stokoe et al., 1994), was the
gift of Sally Johnson (Pennsylvania State University, University Park, PA);
Ras N17, a dominant-negative form of Ras in which amino acid 17 is
changed to Asn (Feig and Cooper, 1988), was the gift of Janet Jackson (The
Scripps Research Institute, La Jolla, CA); Raf-ATP
 , a dominant-negative
form of c-Raf made by generating a point mutation in the ATP binding re-
gion (Kolch et al., 1991), was the gift of Deborah Morrison (National Can-
cer Institute, Bethesda, MD); Ras G12V, a dominant-active form of Ras
made by generating a point mutation at amino acid 12 of Ras (Bos, 1989),
was the gift of Janet Jackson; and FRNK, a dominant-negative form of FAK
found endogenously lacking the kinase domain (Cobb et al., 1994), was
the gift of TJ Parsons (University of Virginia, Charlottesville, VA). PAK83–149
was generated as a PCR product from full-length PAK as described previ-
ously (Zhao et al., 1998).
Chicken CAM angiogenesis assay and treatments
Angiogenesis assays were performed essentially as described previously
(Brooks et al., 1994b). Filter discs saturated with high titer RCAS retrovirus
or anti-integrin antibodies (50  g) along with 2.0  g/ml bFGF or VEGF
were placed on the CAMs of 10-d-old chick embryos. The growth factor
doses were chosen based on dose-response studies in which saturable and
maximal angiogenic responses were seen at 100 ng/ml of each growth fac-
tor. We chose a 20-fold higher dose to eliminate any issues with integrin
specificity. After 72 h, filter discs and associated CAM tissues were har-
vested and quantified. Angiogenesis was assessed as the number of visible
blood vessel branchpoints within the defined area of the filter discs. At
least 20 CAMs were used for each treatment.
Immunoprecipitation and immunoblotting
Biochemical assays of chick angiogenic tissues were done essentially as
described previously (Eliceiri et al., 1998). In brief, tissues were harvested
and snap frozen in liquid nitrogen at the described time points, homoge-
nized in radioimmunoprecipitation (RIPA) buffer, centrifuged at 15,000 g,
and assayed for total protein using the BCA reagent (Pierce Chemical Co.).
Equivalent amounts of protein (400–700  g) were immunoprecipitated
with either anti-c-Raf or anti-PAK antibodies bound to protein A–Sepha-
rose beads. Whole-cell lysates or immunoprecipitates were washed with
RIPA, separated using SDS-PAGE, transferred to nitrocellulose, blocked
with 3% BSA in TBS with 0.1% Tween 20, and exposed to the described
primary antibodies. Antibody binding was detected using HRP-conjugated
goat anti–rabbit or anti–mouse antibodies and ECL (Amersham Bio-
sciences).
Immunofluorescence and microscopy
Immunofluorescent assays were performed essentially as described previ-
ously, with minor modifications (Eliceiri et al., 1998). Cryosections of
CAMs treated with either bFGF or VEGF were examined for the tissue dis-
tribution of phosphorylated ERK or c-Raf using primary antibodies directed
against phosphorylated ERK (Cell Signaling Technologies) or c-Raf phos-
phorylated at S338 (Upstate Biotechnology). CAM sections were treated as
described previously (Eliceiri et al., 1998), removed from embryos, washed
in PBS, embedded in O.C.T. compound (Sakura Finetek), and snap frozen
in liquid nitrogen. Sections of 4- m thick CAM tissue were cut, fixed in ac-
etone for 30 s, and stored at  70 C until use. Tissue sections were pre-
pared for immunostaining by a brief rinse in PBS, a block in 1:5 dilution of
block Hen (Aves Labs), and incubation in a 1:50 dilution of primary anti-
body for 1 h. After 20 min of PBS washes, slides were incubated in Alexa
®
488–labeled secondary antibodies (Molecular Probes, Inc.) for 2 h at
1:500. Slides were mounted, and images were collected on a microscope
(Axiovert 100; Carl Zeiss, MicroImaging, Inc.) with a 20  0.7 NA lens with
a cooled CCD camera (model CE200A; Photometrics) as 12-bit, 512   384
pixel arrays using fluorescein filter sets from Chroma Technology Corp.
Kinase assays for Ras, Raf, Src, and PAK
Ras activity was quantitated essentially as described previously (Taylor and
Shalloway, 1996). In brief, amino acids 1–149 of c-Raf were expressed in
pGEX-RBD in order to obtain a GST fusion protein expressing the active
Ras-binding domain of c-Raf. GST–RBD expression in transformed Esche-
richia coli was induced with 1 mM IPTG for 1–2 h, and the fusion protein
was purified on glutathione-Sepharose beads. The beads were washed in a
solution containing 20 mM Hepes, pH 7.5, 120 mM NaCl, 10% glycerol,
0.5% NP-40, 2 mM EDTA, 10  g ml
 1 leupeptin, and 10  g ml
 1 aproti-
nin, stored in the same buffer at 4 C, and used within 2–3 d of preparation.
For affinity precipitation, lysates were incubated with GST–RBD prebound
to glutathione-Sepharose ( 15  l packed beads;  15–30  g protein) for
30 min at 4 C with rocking. Bound proteins were eluted with SDS–PAGE
sample buffer, resolved on 11% acrylamide gels, and subjected to Western
blotting with anti-pan Ras (Transduction Laboratories). c-Raf activity was
quantitated essentially as described previously (Hood and Granger, 1998).
In brief, c-Raf immunoprecipitates were incubated with kinase-inactive
MEK-1-GST (Upstate Biotechnology) as a substrate for 20 min at 30 C in
40  l reaction buffer (25 mM Hepes, pH 7.4, 25 mM glycerophosphate, 1
mM dithiothreitol, 10 mM MnCl2, 100  M ATP, and 10  Ci of [
32P]ATP
(ICN Biomedicals). The assay was terminated by addition of Laemmli
buffer and boiling, followed by size fractionation on 12% SDS-PAGE, gel
drying, and autoradiography. Src activity was quantitated as described pre-
viously (Eliceiri et al., 1999). PAK activity was quantitated essentially as
described previously (Zenke et al., 1999). In brief, immunoprecipitated
Pak was incubated in kinase buffer (50 mM Hepes/NaOH, pH 7.5, 10 mM
MgCl2, 2 mM MnCl2, 0.2 mM DTT, and 5  g myelin basic protein) con-
taining 20  M ATP and 5  Ci [
32P]ATP. The reactions were incubated for
30 min at 30 C and stopped by addition of sample buffer, followed by size
fractionation on 12% SDS-PAGE, gel drying, and autoradiography.
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